This document summarizes an RNA project focused on inhibition of Dipeptidyl peptidase-IV (DPP-IV), a treatment for Type 2 Diabetes. Key components included: 1) An Internal Ribosome Entry Site (IRES) to allow translation of multiple protein coding regions. Two IRES sequences from EMCV and NKRF were characterized. 2) A neomycin gene to confer antibiotic resistance for selection. 3) An aptazyme as an RNA "kill switch" activated by theophylline. 4) siRNA targeting the 3' untranslated region of DPP-IV mRNA for cleavage. 5) An RNA-dependent RNA polymerase (